Get the Stockscreener App
258.03
1.51%
-3.96
After Hours:
258.03
Natera Inc stock is traded at $258.03, with a volume of 977.58K.
It is down -1.51% in the last 24 hours and down -1.48% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$261.99
Open:
$263.83
24h Volume:
977.58K
Relative Volume:
0.66
Market Cap:
$36.95B
Revenue:
$2.50B
Net Income/Loss:
$-226.32M
P/E Ratio:
-157.22
EPS:
-1.6412
Net Cash Flow:
$71.51M
1W Performance:
-1.75%
1M Performance:
-1.48%
6M Performance:
+7.36%
1Y Performance:
+85.77%
1-Day Range:
$257.00
$267.27
1-Week Range:
$255.66
$273.00
52-Week Range:
$131.81
$288.04
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
258.03 | 37.52B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
559.53 | 211.18B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.50 | 134.62B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
556.20 | 42.94B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
137.89 | 39.14B | 7.23B | 1.41B | 1.09B | 4.979 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | William Blair | Outperform |
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Form 144 NATERA For: 27 July By Investing.com - Investing.com Canada
NTRA (NTRA) affiliate plans sale of 68,976 shares after RSU grant - Stock Titan
Company insider Jonathan Sheena (NTRA) files notice to sell more common stock - Stock Titan
Planned sale of 873 NTRA shares and prior insider stock transactions - Stock Titan
Planned sale of 998 NTRA shares follows earlier 2026 insider trades - Stock Titan
Planned insider stock sale disclosed by NTRA filer John Fesko - Stock Titan
E*TRADE Corporation (NTRA) insider Steven Chapman plans $566K stock sale - Stock Titan
NTRA company insider Michael Brophy plans $202K stock sale in 2026 - Stock Titan
NTRA|Natera Inc|Price:264.800|Chg%:+2.810 - TradingKey
Natera Inc (NTRA) Balance Sheet - TradingKey
Natera Inc (NTRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Natera Inc (NTRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Natera, Inc. (NTRA) stock price, news, quote and history - Yahoo Finance UK
What's Driving Natera's Recent Stock Action, and Why Are Insiders Selling - Kavout | AI
Natera, Inc. (NTRA) options chain - Yahoo Finance Australia
Natera (NTRA) Stock Looks Stretched On Sales Yet Strong On Returns - simplywall.st
Natera, Inc. (NTRA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Natera Inc (NTRA) Institutional Confidence - TradingKey
Natera Inc|Price:261.990|Chg%:-2.700 - TradingKey
NTRA|Natera Inc|Price:261.990|Chg%:-2.700 - TradingKey
What's Driving Natera's Recent Stock Action and Insider Selling - Kavout | AI
Natera Inc (NTRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Natera Inc (NTRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
3 Reasons We’re Fans of Natera (NTRA) - Yahoo Finance
NTRA5169220 Bond Profile — Key Metrics - TradingView
Natera (NTRA) Gets a Buy from BTIG - The Globe and Mail
NTRA|Natera Inc|Price:264.550|Chg%:+0.330 - TradingKey
Natera Inc (NTRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Natera Inc. (NTRA) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
J.P. Morgan Remains a Buy on Natera (NTRA) - The Globe and Mail
Natera (NTRA) Reveals Promising Advances in Merkel Cell Carcinom - GuruFocus
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring - Sahm
Natera’s Signatera test outperforms standard MCC monitoring tool By Investing.com - Investing.com South Africa
Natera’s Signatera test outperforms standard MCC monitoring tool - Investing.com
Natera Inc. (NTRA) Q1 2023 Earnings ReportResults, Call & Slides - TipRanks
What's Driving Natera's Recent Stock Action - Kavout | AI
Form 4 Natera Inc For: 21 July By Investing.com - Investing.com South Africa
Natera co-founder Sheena sells $410,825 of company stock - Investing.com UK
Natera co-founder Sheena sells $410,825 of company stock By Investing.com - Investing.com South Africa
Natera director Rowan Chapman sells $37,100 in shares - Investing.com UK
Natera Inc. (NTRA) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Natera director Rowan Chapman sells $37,100 in shares By Investing.com - Investing.com South Africa
Natera stock trades steady as genetic testing growth supports recent earnings - Ad-hoc-news.de
(NTRA) Volatility Zones as Tactical Triggers - Stock Traders Daily
Natera Inc. (NTRA) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Natera Inc. (NTRA) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Natera Inc. (NTRA) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Natera (NTRA) On Prospera Coverage Expansion And Revenue Strength Looks Fully Valued - simplywall.st
Natera co-founder, Director Sheena Jonathan disposes of 1,500 common shares worth $410,322.91 - Bitget
Natera director Rowan Chapman sells $37,100 in company stock - Investing.com UK
Natera director Rowan Chapman sells $37,100 in company stock By Investing.com - Investing.com South Africa
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):